GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fabino Life Sciences Ltd (BOM:543444) » Definitions » EV-to-EBIT

Fabino Life Sciences (BOM:543444) EV-to-EBIT : 50.91 (As of May. 21, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Fabino Life Sciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Fabino Life Sciences's Enterprise Value is ₹64.7 Mil. Fabino Life Sciences's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was ₹1.3 Mil. Therefore, Fabino Life Sciences's EV-to-EBIT for today is 50.91.

The historical rank and industry rank for Fabino Life Sciences's EV-to-EBIT or its related term are showing as below:

BOM:543444' s EV-to-EBIT Range Over the Past 10 Years
Min: 50.91   Med: 182.66   Max: 368.9
Current: 50.91

During the past 5 years, the highest EV-to-EBIT of Fabino Life Sciences was 368.90. The lowest was 50.91. And the median was 182.66.

BOM:543444's EV-to-EBIT is ranked worse than
86.53% of 668 companies
in the Drug Manufacturers industry
Industry Median: 17.955 vs BOM:543444: 50.91

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Fabino Life Sciences's Enterprise Value for the quarter that ended in Sep. 2023 was ₹63.0 Mil. Fabino Life Sciences's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was ₹1.3 Mil. Fabino Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 2.02%.


Fabino Life Sciences EV-to-EBIT Historical Data

The historical data trend for Fabino Life Sciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fabino Life Sciences EV-to-EBIT Chart

Fabino Life Sciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBIT
- - - 72.45 254.47

Fabino Life Sciences Semi-Annual Data
Mar19 Mar20 Mar21 Mar22 Sep22 Mar23 Sep23
EV-to-EBIT Get a 7-Day Free Trial - 72.45 - 254.47 -

Competitive Comparison of Fabino Life Sciences's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Fabino Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fabino Life Sciences's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fabino Life Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Fabino Life Sciences's EV-to-EBIT falls into.



Fabino Life Sciences EV-to-EBIT Calculation

Fabino Life Sciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=64.708/1.271
=50.91

Fabino Life Sciences's current Enterprise Value is ₹64.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fabino Life Sciences's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was ₹1.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fabino Life Sciences  (BOM:543444) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Fabino Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 ) =EBIT / Enterprise Value (Q: Sep. 2023 )
=1.271/62.965
=2.02 %

Fabino Life Sciences's Enterprise Value for the quarter that ended in Sep. 2023 was ₹63.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fabino Life Sciences's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was ₹1.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fabino Life Sciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Fabino Life Sciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Fabino Life Sciences (BOM:543444) Business Description

Traded in Other Exchanges
N/A
Address
Murthal Road,, Shubham Garden, Jeevan Vihar Extension Near, Sonipat, HR, IND, 131001
Fabino Life Sciences Ltd is a pharmaceutical company. It is engaged in manufacturing, marketing, trading and packing of pharmaceutical and other wellness-focused consumer products. It offers a wide range of allopathic, Food and wellness, Veterinary, Multi-vitamin and herbal products. The company currently supplies in Haryana, Delhi, parts of Punjab, Himachal Pradesh, Eastern Uttar Pradesh, Orissa, and Jharkhand, and parts of West Bengal, Andhra Pradesh, and Nepal.

Fabino Life Sciences (BOM:543444) Headlines

No Headlines